CTMSDG's next meeting will be October 4th from 5 - 8:00. Space is limited.
This event will be held at the Four Points Sheraton Hotel, Located in Meriden, CT
Title: Defining Phenotypic Precision Medicine Using LC-HRMS Stable Isotope Label Metabolic Flux Analysis by Matthew Blatnik, John K. Meissen, David A. Pirman, Russell Miller
Abstract: Stable label isotope tracing in biological systems is an emerging technique that will help shape modern precision medicine based therapeutic strategies. Many disease intervention programs aim to influence protein-substrate interactions. These interventions will have direct impact on cell metabolism leading to phenotypic metabolic changes. Therefore, probing mechanistic fluxes with carbon-13 labeled molecular probes along with broad LC-HRMS metabolomics based screens are the closest investigators can come to measuring a phenotypic response at the compartmental level. This work will demonstrate that genotype does not always translate to phenotype by exploring uniformly U-13C-glutamine fluxes in primary hepatocytes containing a SNP that increases liver Glutaminase-2 (GLS2) activity. We will also explore the metabolic impact of AMPK activation in ex vivo mouse muscles using a pharmacological tool compound and U-13C-labeled glucose. This work will provide a rather detailed view of cell metabolism related to phenotypic changes from genetic or pharmacological events, illustrate the challenges of LC-HRMS based flux analyses and provide a forward-looking perspective into the field.
About the Speaker: Dr. Matthew Blatnik received his Ph.D. in Biochemistry from the University of South Carolina and his B.S. in Chemistry from Francis Marion University (South Carolina). Currently he works for Pfizer as a team leader for an LC-MS based translational biomarker group supporting cardiovascular, metabolic, neurological inflammation, and oncology programs. As group leader, Dr. Blatnik is heavily involved in Pfizer’s global strategies for metabolomics.